Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2009

View Archived Issues

Cell-based influenza H7 pandemic vaccine safe and immunogenic in phase I trial

Novel nitric oxide synthase inhibitors developed for the prevention of cerebral palsy

Novel candidates for the treatment of psoriasis display clinical efficacy and safety

Novel SCD inhibitors discovered by Daiichi Sankyo

Shire withdraws European MAA for Daytrana transdermal system

Avexa reports 96-week data from phase IIb apricitabine trial in HIV

Clavis Pharma announces phase II elacytarabine results

GE Healthcare claims novel iodine-containing contrast agents

Novel macrocyclic serine protease inhibitors developed by Idenix Pharmaceuticals

Merck KGaA presents novel tyrosinase inhibitors

Orally active synthetic androgen shows promise as male contraceptive in vivo

Astellas Pharma presents novel 5-HT5A receptor ligands

Healthpoint initiates phase II study for cell-based venous leg ulcer therapy

beta-Secretase inhibitors reduce amyloid load in rodent models of Alzheimer's disease

XenoPort receives milestone payments for FDA acceptance of Solzira NDA

Unigene reports phase I PTH results with improved formulation

European Commission approves acquisition of Ciba by BASF

Samtheo and Moffitt sign license agreement for Akt inhibitor LD-101

Concert presents encouraging results from phase I CTP-347 trial

Migenix reports top-line results for Omigard in catheter-related infections

Durect reports phase IIb results for Transdur-Sufentanil in pain

PharmaGap and MD Biosciences sign collaboration agreement for PKCtheta inhibitors

Avanir completes enrollment into phase III STAR trial of Zenvia in PBA

Probable delay in FDA's regulatory review of United Therapeutics' NDA for Tyvaso

Helix receives approval to initiate phase II pharmacokinetic study of interferon alpha-2b

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...